AR and breast cancer: AR overexpression in FMCs was also negatively associated with the clinical stage at diagnosis, as in human breast cancer: according to Alshenawy et al. (2012), 91% (98/107) of AR-positive breast cancers were diagnosed at stages I–II, compared to 58% (25/43) of AR-negative carcinomas [44].